Halozyme Therapeutics (HALO) Other financing activities (2010 - 2021)

Halozyme Therapeutics (HALO) has 12 years of Other financing activities data on file, last reported at $4.3 million in Q4 2021.

• On a quarterly basis, Other financing activities fell 66.19% year-over-year to $4.3 million in Q4 2021; TTM through Dec 2021 was $12.5 million, a 80.22% decrease from a year earlier, with the FY2022 full-year figure at $14.0 million, up 12.08% from the prior year.
• Other financing activities for Q4 2021 stood at $4.3 million, down from $4.6 million in the prior quarter.
• Over the last five years, Other financing activities for HALO reached as high as $19.7 million in Q1 2020 and fell as low as -$602000.0 in Q1 2021.
• Historically, Other financing activities has averaged $5.8 million across 5 years, with a median of $4.3 million in 2017.
• Across the five-year window, Other financing activities plunged 237.89% in 2017 and soared 4491.31% in 2020, its largest moves.
• Year by year, Other financing activities stood at $5.1 million in 2017, then sank by 59.47% to $2.1 million in 2018, then surged by 294.13% to $8.1 million in 2019, then soared by 56.78% to $12.7 million in 2020, then sank by 66.19% to $4.3 million in 2021.
• Per Business Quant data, the three most recent Other financing activities figures were $4.3 million in Q4 2021, $4.6 million in Q3 2021, and $4.2 million in Q2 2021.